Tag Archives: immunotherapy drug

25Feb/19

First CD79b Targeted Therapy! Roche Antibody Drug Conjugate Polatuzumab Vedotin is Given Priority Review by FDA in the United States

February 25, 2019Drug Discovery Research, Immunotherapy Research, Newsantibody production, immunotherapy drug, Therapeutic Antibodybiolabs

Swiss pharmaceutical giant Roche recently announced that the Food and Drug Administration (FDA) has accepted the biologics licensing application (BLA) of polatuzumab vedotin, antibody drug conjugate (ADC), and granted priority review. TheRead More…

13Feb/19

The World’s First Nanobody Drug! Sanofi Cablivi is Approved by FDA for the Treatment of Rare Thrombotic Diseases

February 13, 2019Antibody Engineering Research, Drug Discovery Research, Immunotherapy Researchimmunotherapy drug, Nanobody Drug, Therapeutic Antibodybiolabs

French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the nanobody drug Cablivi (caplacizumab), combined with plasma exchange and immunosuppressive therapy. For the treatment ofRead More…

04Jul/18

Overview on Characteristics of Tumor Immunotherapy

July 4, 2018Drug Discovery Research, Immunotherapy Research, Newsimmunotherapy, immunotherapy drug, monoclonal drug, tumor therapybiolabs

Unlike the mechanism of action of traditional treatments, immunotherapy is uniquely characterized by its long-term response and survival in efficacy, unconventional delayed response and pseudo-progression in response mode, a new assessment endpointRead More…

24Jul/17

The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!

July 24, 2017Immunotherapy Research, NewsCAR-T, FDA, immunotherapy drug, Novartisbiolabs

Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…